The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
Authors:
- 14 September 2019
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 21 (1) , 45-54
Abstract
To estimate the impact of persistence on cost-effectiveness of subcutaneous tumor necrosis factor-α inhibitors (SC-TNFis) from healthcare and societal perspectives in a United Kingdom ankylosing spondylitis (AS) population using a recently published Markov cohort model.Keywords
Funding Information
- Merck
This publication has 30 references indexed in Scilit:
- The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trialAnnals of the Rheumatic Diseases, 2014
- Increased mortality in ankylosing spondylitis is related to disease activityAnnals of the Rheumatic Diseases, 2011
- Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic ReviewClinical Therapeutics, 2011
- Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD registerAnnals of the Rheumatic Diseases, 2011
- The Natural Course of Radiographic Progression in Ankylosing Spondylitis — Evidence for Major Individual Variations in a Large Proportion of PatientsThe Journal of Rheumatology, 2009
- Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic EvaluationsValue in Health, 2007
- Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?Annals of the Rheumatic Diseases, 2005
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countriesAnnals of the Rheumatic Diseases, 2003
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995